Holen Sie sich die Stockscreener-App
328.82
0.46%
-1.52
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt WST?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$330.34
Offen:
$333.27
24-Stunden-Volumen:
465.32K
Relative Volume:
0.55
Marktkapitalisierung:
$23.23B
Einnahmen:
$3.22B
Nettoeinkommen (Verlust:
$542.70M
KGV:
43.96
EPS:
7.4805
Netto-Cashflow:
$458.00M
1W Leistung:
+4.55%
1M Leistung:
+5.37%
6M Leistung:
+22.90%
1J Leistung:
+46.20%
1-Tages-Spanne:
$327.43
$333.40
1-Wochen-Bereich:
$315.24
$336.82
52-Wochen-Spanne:
$206.80
$336.82
West Pharmaceutical Services Inc Stock (WST) Company Profile
Firmenname
West Pharmaceutical Services Inc
Sektor
Telefon
(610) 594-2900
Adresse
530 HERMAN O. WEST DRIVE, EXTON, PA
Compare WST vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
WST
West Pharmaceutical Services Inc
|
328.82 | 23.23B | 3.22B | 542.70M | 458.00M | 7.4805 |
ISRG
Intuitive Surgical Inc
|
411.06 | 145.58B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
146.24 | 40.30B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.85 | 32.60B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.61 | 30.96B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
194.78 | 28.25B | 5.54B | 1.52B | 1.74B | 10.37 |
West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2025-09-15 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-24 | Eingeleitet | Barclays | Equal Weight |
| 2025-03-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-01-08 | Eingeleitet | Citigroup | Buy |
| 2024-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-12-12 | Hochstufung | UBS | Neutral → Buy |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2023-06-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-04-11 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Hold |
| 2022-11-30 | Eingeleitet | UBS | Neutral |
| 2022-10-28 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-10-14 | Eingeleitet | Stephens | Equal-Weight |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-04-24 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-12-12 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-07-26 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-05-01 | Herabstufung | Jefferies | Buy → Hold |
| 2019-04-23 | Eingeleitet | William Blair | Outperform |
| 2018-04-25 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-17 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2017-10-03 | Eingeleitet | Stephens | Equal-Weight |
| 2017-09-15 | Hochstufung | Jefferies | Hold → Buy |
| 2016-10-28 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-09-21 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2016-03-22 | Eingeleitet | Wells Fargo | Outperform |
| 2010-05-14 | Bestätigt | UBS | Neutral |
| 2010-02-23 | Eingeleitet | Jefferies & Co | Buy |
| 2008-12-19 | Eingeleitet | UBS | Neutral |
Alle ansehen
West Pharmaceutical Services Inc Aktie (WST) Neueste Nachrichten
Is Wall Street bullish or bearish on West Pharmaceutical Services stock? - MSN
West Pharmaceutical Stock (US9553061055): Valuation Metrics Under the Microscope on a Quiet Friday - AD HOC NEWS
West Pharmaceutical Stock (US9523901012): Valuation Metrics Under the Microscope - AD HOC NEWS
West Pharma’s GLP-1 Tailwinds Come With A Cybersecurity Footnote - Finimize
West NovaGuard® SA Pro Safety System Recognized for Excellence in Design and User Experience at the India Packaging Awards - Devdiscourse
West Pharmaceutical Services Inc. stock outperforms competitors despite losses on the day - MarketWatch
Reasons to Add Veeva Systems Stock to Your Portfolio for Now - TradingView
West Pharmaceutical Names Thermo Fisher Executive as CEO - MyChesCo
AMN Expands Language Services Portfolio With Jaide Health Deal - TradingView
Motley Fool Wealth Management LLC Reduces Holdings in West Pharmaceutical Services, Inc. $WST - MarketBeat
Here's what to expect from West Pharmaceutical's next earnings report - MSN
West Pharma raised to overweight at Barclays on fundamentals - MSN
West Pharmaceutical Services Inc (WST) Shares Surge 4.7% -- What GF Score of 96 Tells Investors - GuruFocus
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
Barclays Upgrades West Pharmaceutical Services to Overweight From Equalweight, Adjusts PT to $400 From $310 - Moomoo
West Pharmaceutical (WST) Boosted to Overweight with Target Rais - GuruFocus
West Pharmaceutical Services appoints Michel Lagarde as next president, CEO - Pennsylvania Business Report -
West Pharmaceutical Services (NYSE:WST) Reaches New 12-Month HighStill a Buy? - MarketBeat
West Pharma stock upgraded at Barclays (WST:NYSE) - Seeking Alpha
West Pharmaceutical Services stock hits 52-week high at 331.43 USD - Investing.com
Barclays upgrades West Pharmaceutical stock rating on GLP-1 outlook By Investing.com - Investing.com Canada
ING Groep NV Sells 17,581 Shares of West Pharmaceutical Services, Inc. $WST - MarketBeat
Wolfe Research Says West Pharmaceutical Services (WST) is Positioned to Benefit from Injectable Drug Growth - Insider Monkey
Why Is West Pharmaceutical Drawing Attention Amid Injectable Drug Expansion? - Kalkine Media
West Pharmaceutical Services names Michel Lagarde as next CEO, effective Aug. 31 - MSN
Los Angeles Capital Management LLC Has $11.95 Million Position in West Pharmaceutical Services, Inc. $WST - MarketBeat
West Pharmaceutical Services (WST) Stock Analysis: A 12% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
Wolfe Research Initiates Coverage on West Pharmaceutical Services with Outperform RatingStrong Earnings Momentum - newsline.com
Wolfe Research Initiates Coverage on West Pharmaceutical Services (WST) With Outperform RatingGuidance Revision Trend - newsline.com
Wolfe Research Weighs on West Pharmaceutical Services Inc (WST) Stock - Insider Monkey
How The West Pharmaceutical Services (WST) Story Is Evolving With Guidance Buybacks And New Leadership - Yahoo Finance
West Pharmaceutical Services, Inc. $WST Stock Position Decreased by Natixis Advisors LLC - MarketBeat
CIBC Asset Management Inc Acquires 6,915 Shares of West Pharmaceutical Services, Inc. $WST - MarketBeat
WST Technical Analysis | Trend, Signals & Chart Patterns | WEST PHARMACEUTICAL SERVICES (NYSE:WST) - ChartMill
Exton's West Pharmaceutical Services Names New CEO as Eric Green Steps Down After 11 Years - VISTA.Today
What Does Eric Green's Retirement Mean for West Pharmaceutical Services - Kavout
West Pharma names former Thermo Fisher executive Lagarde as CEO - ETPharma.com
Billionaire Bill Gates' Foundation Dumped Microsoft but Loaded Up on This Dividend Champion - Yahoo Finance
West Pharmaceutical Names Michel Lagarde Next CEO - The Globe and Mail
Billionaire Bill Gates' Foundation Dumped Microsoft but Loaded Up on This Dividend Champion - The Motley Fool
West Pharmaceutical Services Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
West Pharmaceutical Services Inc at William Blair Growth Stock Conference Transcript - GuruFocus
West Pharmaceutical Services (WST) Announces Leadership Transiti - GuruFocus
Q1 2026 Life Sciences Earnings Review: PacBio vs. West Pharmaceutical PerformanceNews and Statistics - IndexBox
WST Reiterated by Stephens & Co. -- Price Target Maintained at $360 - GuruFocus
BofA Securities Maintains West Pharmaceutical Services(WST.US) With Buy Rating - Moomoo
West Appoints Michel Lagarde a President and CEO - Contract Pharma
Here's Why You Should Retain AMN Stock in Your Portfolio for Now - TradingView
West Pharmaceutical Services Appoints Michel Lagarde as President and CEO Effective August 31, 2026 - Minichart
West Pharmaceutical (WST) Names Michel Lagarde as New CEO - GuruFocus
West Appoints Michel Lagarde to be President and Chief Executive Officer - GuruFocus
Finanzdaten der West Pharmaceutical Services Inc-Aktie (WST)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):